(JRUB) JPMorgan s Ireland ICAV - Ratings and Ratios
Corporate Bonds, Fixed Income, US Dollar, Investment Grade
Description: JRUB JPMorgan s Ireland ICAV
The JPMorgan ETFs Ireland ICAV - USD Corporate Bond Research Enhanced Index ESG UCITS ETF USD Acc is an exchange-traded fund (ETF) that tracks the Morningstar US Corp Bd TR USD index, providing exposure to USD-denominated corporate bonds. As a research-enhanced index ETF, it aims to outperform the underlying index through a systematic investment approach.
From a performance perspective, the ETF has shown a relatively stable price movement, with a current price of 102.81. The short-term moving averages (SMA20 and SMA50) indicate a slight downward trend, while the long-term SMA200 suggests a more significant decline over the past year. The Average True Range (ATR) of 0.51 (0.50%) implies moderate daily price volatility.
In terms of key performance indicators (KPIs), the ETFs Assets Under Management (AUM) stand at approximately 5.96 billion EUR, indicating a sizable presence in the market. To further evaluate its performance, we can consider metrics such as the ETFs yield, duration, and credit quality. A higher yield may indicate a more attractive income generation profile, while a lower duration may suggest reduced sensitivity to interest rate changes. Additionally, the ETFs ESG (Environmental, Social, and Governance) focus may appeal to investors seeking to align their investments with their values.
To assess the ETFs potential, we can examine its tracking error, which measures the deviation of the ETFs returns from its underlying index. A lower tracking error would indicate a more effective replication of the index. Furthermore, an analysis of the ETFs holdings and sector allocation can provide insights into its credit risk profile and potential areas of concentration.
Additional Sources for JRUB ETF
JRUB ETF Overview
Market Cap in USD | 7,024m |
Category | USD Corporate Bond |
IPO / Inception | 2018-12-05 |
JRUB ETF Ratings
Growth Rating | -10.3 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | -0.42 |
Analysts | - |
Fair Price Momentum | 94.83 EUR |
Fair Price DCF | - |
JRUB Dividends
Currently no dividends paidJRUB Growth Ratios
Growth Correlation 3m | -34.4% |
Growth Correlation 12m | -21.9% |
Growth Correlation 5y | 6.9% |
CAGR 5y | -1.22% |
CAGR/Max DD 5y | -0.09 |
Sharpe Ratio 12m | 0.38 |
Alpha | -7.17 |
Beta | 0.008 |
Volatility | 6.47% |
Current Volume | 7k |
Average Volume 20d | 0k |
As of July 07, 2025, the stock is trading at EUR 102.60 with a total of 7,000 shares traded.
Over the past week, the price has changed by +0.12%, over one month by -1.24%, over three months by -4.81% and over the past year by -2.64%.
Neither. Based on ValueRay´s Analyses, JPMorgan s Ireland ICAV is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -10.28 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JRUB is around 94.83 EUR . This means that JRUB is currently overvalued and has a potential downside of -7.57%.
JPMorgan s Ireland ICAV has no consensus analysts rating.
According to our own proprietary Forecast Model, JRUB JPMorgan s Ireland ICAV will be worth about 102.4 in July 2026. The stock is currently trading at 102.60. This means that the stock has a potential downside of -0.19%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 102.4 | -0.2% |